or Try an Advanced Search...

    Technical Analysis for SPRO - Spero Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 1.25 -4.58% -0.06
    SPRO closed down 4.58 percent on Thursday, November 14, 2024, on 1.33 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical SPRO trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish 0.00%
    Fell Below 50 DMA Bearish 0.00%
    Weak + Overbought Other 0.00%
    Overbought Stochastic Strength 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Gapped Down Weakness 0.00%
    Stochastic Sell Signal Bearish -4.58%
    50 DMA Support Bullish -4.58%
    Narrow Range Bar Range Contraction -4.58%
    Overbought Stochastic Strength -4.58%
    Older End-of-Day Signals for SPRO ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 16 hours ago
    Down 1 ATR about 16 hours ago
    60 Minute Opening Range Breakdown about 17 hours ago
    2x Volume Pace about 19 hours ago
    1.5x Volume Pace about 19 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    SPRO Chart by TradingView
    Basic chart:

    Profile

    Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Bacterial Infections Veterinary Medicine Regulus Therapeutics Antimicrobial Resistance Drug Resistant Bacterial Infections Evolutionary Biology Multi Drug Resistant Bacterial Infections

    Is SPRO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 14 Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates
    Nov 14 Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update
    Nov 14 Earnings Scheduled For November 14, 2024
    Nov 13 Spero Therapeutics Q3 2024 Earnings Preview
    Nov 6 Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth
    Nov 6 Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
    Oct 30 Spero’s stock slides after antibiotic flops in Phase II trial
    Oct 30 Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
    Oct 29 Spero to cut 39% of workforce on failed study, stock plunges 20%
    Oct 29 Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update
    See more SPRO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.89
    52 Week Low 1.01
    Average Volume 240,213
    200-Day Moving Average 1.44
    50-Day Moving Average 1.30
    20-Day Moving Average 1.29
    10-Day Moving Average 1.29
    Average True Range 0.07
    RSI (14) 44.13
    ADX 16.67
    +DI 17.07
    -DI 27.42
    Chandelier Exit (Long, 3 ATRs) 1.15
    Chandelier Exit (Short, 3 ATRs) 1.21
    Upper Bollinger Bands 1.36
    Lower Bollinger Band 1.21
    Percent B (%b) 0.25
    BandWidth 11.30
    MACD Line 0.00
    MACD Signal Line 0.00
    MACD Histogram 0.0017
    Fundamentals Value
    Market Cap 66.25 Million
    Num Shares 53 Million
    EPS 0.39
    Price-to-Earnings (P/E) Ratio 3.21
    Price-to-Sales 1.02
    Price-to-Book 1.35
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.38
    Resistance 3 (R3) 1.39 1.35 1.36
    Resistance 2 (R2) 1.35 1.32 1.35 1.35
    Resistance 1 (R1) 1.30 1.30 1.28 1.29 1.34
    Pivot Point 1.27 1.27 1.26 1.26 1.27
    Support 1 (S1) 1.22 1.23 1.20 1.21 1.16
    Support 2 (S2) 1.18 1.21 1.18 1.15
    Support 3 (S3) 1.13 1.18 1.14
    Support 4 (S4) 1.12